OCPs are C/I in pts receiving:
**Core Concept**
OCPs (Oral Contraceptive Pills) are contraindicated in patients receiving certain medications or with specific medical conditions due to the potential for increased risk of thromboembolic events. The primary concern is the interaction between OCPs and other drugs that affect the coagulation pathway or have a pro-thrombotic effect.
**Why the Correct Answer is Right**
The correct answer is related to the mechanism of OCPs and their interaction with other medications. OCPs contain estrogen and progestin, which can increase the risk of thromboembolic events. Certain medications, such as tamoxifen, can also increase the risk of thromboembolic events, and combining them with OCPs can further exacerbate this risk. The interaction is thought to be due to the additive effect of estrogen on the coagulation pathway, leading to an increased risk of clot formation.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because there is no established contraindication between OCPs and this medication. In fact, some medications may be used to treat conditions associated with OCP use.
**Option B:** This option is incorrect because while this medication may have some effects on the coagulation pathway, it is not a contraindication for OCP use.
**Option C:** This option is incorrect because there is no established contraindication between OCPs and this medication. In fact, some medications may be used to treat conditions associated with OCP use.
**Clinical Pearl / High-Yield Fact**
When prescribing OCPs, it is essential to consider the patient's medical history, including any prior thromboembolic events or conditions that may increase the risk of clot formation. A thorough medical history and physical examination can help identify patients who may be at increased risk and require alternative contraception methods.
**Correct Answer: C. Tamoxifen. Tamoxifen is a selective estrogen receptor modulator (SERM) used in the treatment of breast cancer, and it can increase the risk of thromboembolic events when combined with OCPs.**